Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bayer CropScience Limited (BAYERCROP.NS)
Thane, IN
Bayer CropScience Limited, founded in Thane, India, in 1958, is a diversified enterprise involved in various sectors, including agriculture, pharmaceuticals, and consumer health, with a global reach encompassing India, Germany, and Bangladesh, among other international markets. The company's agricultural segment is dedicated to the manufacturing, sales, and distribution of an extensive array of crop protection products, such as insecticides, fungicides, and herbicides, alongside other specialized agrochemicals. It also provides hybrid seeds, including corn and paddy varieties, to agriculturalists. In the pharmaceutical domain, Bayer CropScience delivers medicines primarily targeting cardiology, gynecology, diabetes, oncology, and ophthalmology. Additionally, it supplies advanced diagnostic imaging technologies, such as computed tomography (CT), X-ray, and magnetic resonance imaging (MRI) equipment, together with essential contrast agents. Its consumer health division offers a selection of products designed for daily wellness and the management of minor ailments. Pioneering digital solutions for farming, the company provides platforms like FarmRiseTM and other predictive systems. These tools integrate and analyze vast amounts of data from sources such as farm machinery, satellites, field sensors, irrigation networks, and drones. Leveraging data science and sophisticated predictive analytics, these systems furnish farmers with actionable insights to optimize their decision-making. The company also actively exports its comprehensive range of products.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.56% | +6.23% | -1.29% | -1.21% | +0.95% | +1.27% | -18.65% | +12.07% | -12.71% | +18.20% | +730.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Agricultural Inputs: +9.5%+3.7% Q1'26: +5.1% (vs Q1'25)
-
EPS growth Agricultural Inputs: +23.0%+21.3% Q1'26: +13.1% (vs Q1'25)
-
FCF margin FCF growth · Agricultural Inputs: +27.6%+16.7% ★ Q1'26: -6.2% (vs Q1'25)
-
EBIT margin Agricultural Inputs: +9.7%+13.7% ★ Q1'26: +15.0% (vs Q1'25)
-
ROIC Agricultural Inputs: +7.4%+40.1% ★ Q1'26: +33.1% (vs Q1'25)
-
Share dilution Agricultural Inputs: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Agricultural Inputs: 0.03×0.09× ★ Q1'26: 0.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 6 EPS Ana. |
Mar 2027 8 Rev. Ana. 8 EPS Ana. |
Mar 2028 3 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.39B
est: 21.32B (-4.4%)
|
22.04B
est: 22.45B (-1.8%)
|
27.25B
est: 27.14B (+0.4%)
|
37.23B
est: 31.35B (+18.8%)
|
37.23B
est: 37.25B (-0.1%)
|
27.84B
est: 37.49B (-25.7%)
|
28.15B
est: 37.40B (-24.7%)
|
27.17B
est: 27.20B (-0.1%)
|
31.75B
est: 28.67B (+10.7%)
|
36.09B
est: 35.05B (+3.0%)
|
42.61B
est: 40.48B (+5.3%)
|
47.34B
est: 45.67B (+3.7%)
|
51.40B
est: 52.16B (-1.5%)
|
51.06B
est: 53.81B (-5.1%)
|
54.73B
est: 53.53B (+2.3%)
|
57.06B
56.60B – 57.57B
+6.6% YoY
|
62.61B
61.54B – 63.78B
+9.7% YoY
|
68.90B
67.72B – 70.19B
+10.0% YoY
|
| EBITDA |
2.40B
est: 3.52B (-31.9%)
|
2.51B
est: 2.35B (+6.8%)
|
3.71B
est: 3.19B (+16.5%)
|
5.25B
est: 19.06B (-72.5%)
|
5.25B
est: 7.06B (-25.6%)
|
4.61B
est: 6.76B (-31.8%)
|
4.38B
est: 5.10B (-14.3%)
|
4.27B
est: 4.17B (+2.5%)
|
5.10B
est: 4.41B (+15.6%)
|
7.05B
est: 6.52B (+8.1%)
|
7.80B
est: 8.10B (-3.8%)
|
7.90B
est: 9.45B (-16.4%)
|
8.86B
est: 10.23B (-13.4%)
|
9.43B
est: 10.90B (-13.4%)
|
6.43B
est: 8.83B (-27.2%)
|
9.41B
9.33B – 9.49B
+6.6% YoY
|
10.32B
10.15B – 10.52B
+9.7% YoY
|
11.36B
11.17B – 11.57B
+10.0% YoY
|
| EBIT |
2.07B
est: 3.35B (-38.2%)
|
2.06B
est: 2.05B (+0.7%)
|
3.35B
est: 2.10B (+59.5%)
|
5.01B
est: 3.61B (+38.6%)
|
5.01B
est: 4.51B (+10.9%)
|
4.37B
est: 5.10B (-14.2%)
|
4.10B
est: 3.92B (+4.6%)
|
3.97B
est: 3.23B (+22.8%)
|
4.69B
est: 3.87B (+21.2%)
|
6.62B
est: 5.43B (+21.8%)
|
7.39B
est: 6.55B (+12.7%)
|
7.50B
est: 7.64B (-1.8%)
|
8.47B
est: 8.27B (+2.4%)
|
9.05B
est: 8.81B (+2.7%)
|
6.07B
est: 8.40B (-27.8%)
|
8.95B
8.88B – 9.03B
+6.6% YoY
|
9.82B
9.66B – 10.01B
+9.7% YoY
|
10.81B
10.63B – 11.01B
+10.0% YoY
|
| Net Income |
1.32B
est: 1.85B (-28.9%)
|
1.39B
est: 1.39B (+0.4%)
|
11.62B
est: 1.68B (+591.4%)
|
3.83B
est: 13.42B (-71.5%)
|
3.83B
est: 3.55B (+7.7%)
|
3.15B
est: 3.90B (-19.2%)
|
2.91B
est: 2.93B (-0.6%)
|
3.00B
est: 2.36B (+27.0%)
|
3.37B
est: 2.98B (+13.1%)
|
4.75B
est: 4.01B (+18.3%)
|
4.93B
est: 5.73B (-14.0%)
|
6.45B
est: 6.68B (-3.4%)
|
7.58B
est: 7.24B (+4.8%)
|
7.41B
est: 7.71B (-3.9%)
|
5.68B
est: 5.60B (+1.4%)
|
6.69B
6.42B – 6.89B
+19.4% YoY
|
7.64B
6.69B – 8.12B
+14.2% YoY
|
8.80B
8.60B – 9.01B
+15.2% YoY
|
| SGA |
—
est: 3.16B (-100.0%)
|
2.15B
est: 5.57B (-61.4%)
|
5.24B
est: 6.34B (-17.3%)
|
3.99B
est: 6.80B (-41.3%)
|
3.99B
est: 8.53B (-53.2%)
|
4.07B
est: 7.01B (-41.9%)
|
4.13B
est: 6.69B (-38.3%)
|
4.33B
est: 5.85B (-26.0%)
|
6.01B
est: 6.70B (-10.3%)
|
5.73B
est: 11.55B (-50.4%)
|
5.73B
est: 11.13B (-48.5%)
|
7.84B
est: 12.97B (-39.6%)
|
8.62B
est: 14.05B (-38.7%)
|
6.90B
est: 14.96B (-53.9%)
|
7.53B
est: 7.92B (-5.0%)
|
8.45B
8.38B – 8.52B
+6.6% YoY
|
9.27B
9.11B – 9.44B
+9.7% YoY
|
10.20B
10.03B – 10.39B
+10.0% YoY
|
| EPS |
33.30
est: 41.16 (-19.1%)
|
35.19
est: 47.27 (-25.6%)
|
294.11
est: 65.20 (+351.1%)
|
104.59
est: 69.64 (+50.2%)
|
104.59
est: 106.83 (-2.1%)
|
87.34
est: 93.51 (-6.6%)
|
82.31
est: 106.87 (-23.0%)
|
86.16
est: 83.55 (+3.1%)
|
78.46
est: 91.88 (-14.6%)
|
105.58
est: 115.70 (-8.7%)
|
109.72
est: 130.39 (-15.9%)
|
143.58
est: 117.79 (+21.9%)
|
168.71
est: 149.79 (+12.6%)
|
164.77
est: 182.64 (-9.8%)
|
126.38
est: 117.14 (+7.9%)
|
148.80
142.88 – 153.20
+27.0% YoY
|
169.92
148.79 – 180.77
+14.2% YoY
|
195.81
191.46 – 200.56
+15.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Simon Thorsten Wiebusch | Vice Chairman, MD & Chief Executive Officer | 87M | male |
| Bharati Shetty | Company Secretary & Compliance Officer | 5M | female |
| Vinit Jindal | Whole-Time Executive Director & Chief Financial Officer | 4M | male |
| Dinesh S. Bapat | Country Group Mngr of Environmental Science for India, Sri Lanka & for Nepal | 2M | male |
| Shweta Rai | Country Division Head of the Pharmaceutical Division | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BAYERCROP.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
